Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15294863 | 0.86 | TACR1 (0.32) | TACR1SMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL902926 | 0.82 | ALDH1A1 (0.33) | TACR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16507385 | 0.79 | ALDH1A1 (0.32) | TACR1SMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL15294861 | 0.79 | ALDH1A1 (0.32) | TACR1SMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL903041 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL21203107 | 0.76 | LY96 (0.34) | SMN1; SMN2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL15294864 | 0.71 | CA12 (0.33) | SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL902994 | 0.69 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL15295026 | 0.69 | NNMT (0.36) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL16507190 | 0.69 | NNMT (0.36) | SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | TACR1 709/4885SMN1; SMN2 4016/4885ALDH1A1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.